Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1990 Mar;211(3):312–316.

Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.

J R Fletcher 1, A G DiSimone 1, M A Earnest 1
PMCID: PMC1358436  PMID: 2178565

Abstract

Exogenous platelet activating factor (PAF) causes hypotension, plasma extravasation, metabolic acidosis, and death. These effects are similar to those of endotoxin as well as the eicosanoids. A specific PAF receptor antagonist, BN52021, was used to determine its effects on the hemodynamic events, the eicosanoid production, and on survival in severe rat endotoxemia. Endotoxin alone significantly produced hypotension, prostaglandins (TxB2, PGE2) release, and death. In contrast pretreatment with BN52021, a specific PAF receptor antagonist, significantly altered the hypotension, significantly attenuated the eicosanoid release, and improved the survival rate (p less than 0.01). These findings suggest that PAF receptor activation is an early event in endotoxemia. Eicosanoid release in endotoxemia could be related to PAF synthesis and PAF receptor activation. These findings support the hypothesis that there may be an intimate relationship between PAF and the eicosanoids and that in endotoxemia some of the effects of PAF may be mediated via the cyclo-oxygenase pathway.

Full text

PDF
312

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnot S., Lefort J., Braquet P., Vargaftig B. B. Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea-pig. Prostaglandins. 1986 Dec;32(6):791–802. doi: 10.1016/0090-6980(86)90090-0. [DOI] [PubMed] [Google Scholar]
  2. Albert D. H., Snyder F. Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation. J Biol Chem. 1983 Jan 10;258(1):97–102. [PubMed] [Google Scholar]
  3. Baranes J., Hellegouarch A., Le Hegarat M., Viossat I., Auguet M., Chabrier P. E., Braquet P. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacol Res Commun. 1986 Aug;18(8):717–737. doi: 10.1016/0031-6989(86)90114-1. [DOI] [PubMed] [Google Scholar]
  4. Benveniste J., Chignard M., Le Couedic J. P., Vargaftig B. B. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. Thromb Res. 1982 Mar 1;25(5):375–385. doi: 10.1016/0049-3848(82)90128-1. [DOI] [PubMed] [Google Scholar]
  5. Bessin P., Bonnet J., Apffel D., Soulard C., Desgroux L., Pelas I., Benveniste J. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol. 1983 Jan 21;86(3-4):403–413. doi: 10.1016/0014-2999(83)90190-5. [DOI] [PubMed] [Google Scholar]
  6. Blackwell G. J., Flower R. J. Inhibition of phospholipase. Br Med Bull. 1983 Jul;39(3):260–264. doi: 10.1093/oxfordjournals.bmb.a071830. [DOI] [PubMed] [Google Scholar]
  7. Bone R. C., Fisher C. J., Jr, Clemmer T. P., Slotman G. J., Metz C. A., Balk R. A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987 Sep 10;317(11):653–658. doi: 10.1056/NEJM198709103171101. [DOI] [PubMed] [Google Scholar]
  8. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  9. Burhop K. E., Garcia J. G., Selig W. M., Lo S. K., van der Zee H., Kaplan J. E., Malik A. B. Platelet-activating factor increases lung vascular permeability to protein. J Appl Physiol (1985) 1986 Dec;61(6):2210–2217. doi: 10.1152/jappl.1986.61.6.2210. [DOI] [PubMed] [Google Scholar]
  10. Burhop K. E., van der Zee H., Bizios R., Kaplan J. E., Malik A. B. Pulmonary vascular response to platelet-activating factor in awake sheep and the role of cyclooxygenase metabolites. Am Rev Respir Dis. 1986 Sep;134(3):548–554. doi: 10.1164/arrd.1986.134.3.548. [DOI] [PubMed] [Google Scholar]
  11. Caillard C. G., Mondot S., Zundel J. L., Julou L. Hypotensive activity of PAF-acether in rats. Agents Actions. 1982 Dec;12(5-6):725–730. doi: 10.1007/BF01965093. [DOI] [PubMed] [Google Scholar]
  12. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  13. Casals-Stenzel J. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Eur J Pharmacol. 1987 Mar 17;135(2):117–122. doi: 10.1016/0014-2999(87)90602-9. [DOI] [PubMed] [Google Scholar]
  14. Chang S. W., Feddersen C. O., Henson P. M., Voelkel N. F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest. 1987 May;79(5):1498–1509. doi: 10.1172/JCI112980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chilton F. H., Ellis J. M., Olson S. C., Wykle R. L. 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. J Biol Chem. 1984 Oct 10;259(19):12014–12019. [PubMed] [Google Scholar]
  16. Chilton F. H., O'Flaherty J. T., Ellis J. M., Swendsen C. L., Wykle R. L. Metabolic fate of platelet-activating factor in neutrophils. J Biol Chem. 1983 May 25;258(10):6357–6361. [PubMed] [Google Scholar]
  17. Chilton F. H., O'Flaherty J. T., Ellis J. M., Swendsen C. L., Wykle R. L. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. J Biol Chem. 1983 Jun 25;258(12):7268–7271. [PubMed] [Google Scholar]
  18. Chilton F. H., O'Flaherty J. T., Walsh C. E., Thomas M. J., Wykle R. L., DeChatelet L. R., Waite B. M. Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. J Biol Chem. 1982 May 25;257(10):5402–5407. [PubMed] [Google Scholar]
  19. Dembinska-Kiec A., Peskar B. A., Muller M. K., Peskar B. M. The effects of platelet-activating factor on flow rate and eicosanoid release in the isolated perfused rat gastric vascular bed. Prostaglandins. 1989 Jan;37(1):69–91. doi: 10.1016/0090-6980(89)90033-6. [DOI] [PubMed] [Google Scholar]
  20. Doebber T. W., Wu M. S., Robbins J. C., Choy B. M., Chang M. N., Shen T. Y. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun. 1985 Mar 29;127(3):799–808. doi: 10.1016/s0006-291x(85)80014-0. [DOI] [PubMed] [Google Scholar]
  21. Ezra D., Feuerstein G., Ramwell P. W., Hayes E., Goldstein R. E. Effects of platelet-activating factor on coronary hemodynamics and coronary venous plasma levels of TXB2, 6-keto-PGF1 alpha, and leukotriene C4 immunoreactivity in the intact domestic pig heart. Adv Prostaglandin Thromboxane Leukot Res. 1985;13:19–21. [PubMed] [Google Scholar]
  22. Fletcher J. R., Ramwell P. W. E. coli endotoxin shock in the dog; treatment with lidocaine or indomethacin. Br J Pharmacol. 1978 Oct;64(2):185–191. doi: 10.1111/j.1476-5381.1978.tb17288.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fletcher J. R., Ramwell P. W. Lidocaine or indomethacin improves survival in baboon endotoxin shock. J Surg Res. 1978 Mar;24(3):154–160. doi: 10.1016/0022-4804(78)90168-3. [DOI] [PubMed] [Google Scholar]
  24. Handley D. A., Van Valen R. G., Tomesch J. C., Melden M. K., Jaffe J. M., Ballard F. H., Saunders R. N. Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology. 1987 Apr;13(2):125–132. doi: 10.1016/0162-3109(87)90049-x. [DOI] [PubMed] [Google Scholar]
  25. Haroldsen P. E., Voelkel N. F., Henson J. E., Henson P. M., Murphy R. C. Metabolism of platelet-activating factor in isolated perfused rat lung. J Clin Invest. 1987 Jun;79(6):1860–1867. doi: 10.1172/JCI113028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Heffner J. E., Shoemaker S. A., Canham E. M., Patel M., McMurtry I. F., Morris H. G., Repine J. E. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. J Clin Invest. 1983 Feb;71(2):351–357. doi: 10.1172/JCI110776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Iñarrea P., Gomez-Cambronero J., Pascual J., Ponte M. C., Hernando L., Sánchez-Crespo M. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. Immunopharmacology. 1985 Feb;9(1):45–52. doi: 10.1016/0162-3109(85)90046-3. [DOI] [PubMed] [Google Scholar]
  28. McManus L. M., Hanahan D. J., Demopoulos C. A., Pinckard R. N. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol. 1980 Jun;124(6):2919–2924. [PubMed] [Google Scholar]
  29. Mehta J., Wargovich T., Nichols W. W. Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog. Prostaglandins Leukot Med. 1986 Jan;21(1):87–95. doi: 10.1016/0262-1746(86)90166-6. [DOI] [PubMed] [Google Scholar]
  30. Mueller H. W., O'Flaherty J. T., Wykle R. L. Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. Lipids. 1982 Feb;17(2):72–77. doi: 10.1007/BF02535178. [DOI] [PubMed] [Google Scholar]
  31. Natarajan V., Zuzarte-Augustin M., Schmid H. H., Graff G. The alkylacyl and alkenylacyl glycerophospholipids of human platelets. Thromb Res. 1983 Apr 15;30(2):119–125. doi: 10.1016/0049-3848(83)90234-7. [DOI] [PubMed] [Google Scholar]
  32. Renooij W., Snyder F. Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. Biochim Biophys Acta. 1981 Feb 23;663(2):545–556. doi: 10.1016/0005-2760(81)90182-x. [DOI] [PubMed] [Google Scholar]
  33. Sanchez Crespo M., Inarrea P., Nieto M. L., Fernandez-Gallardo S. Evidence of a role for PAF-acether in the pathophysiology of the shock state. Pharmacol Res Commun. 1986 Aug;18 (Suppl):181–196. doi: 10.1016/0031-6989(86)90051-2. [DOI] [PubMed] [Google Scholar]
  34. Short B. L., Gardiner M., Walker R. I., Jones S. R., Fletcher J. R. Indomethacin improves survival in gram-negative sepsis. Adv Shock Res. 1981;6:27–36. [PubMed] [Google Scholar]
  35. Sugiura T., Onuma Y., Sekiguchi N., Waku K. Ether phospholipids in guinea pig polymorphonuclear leukocytes and macrophages. Occurrence of high levels of 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine. Biochim Biophys Acta. 1982 Sep 14;712(3):515–522. [PubMed] [Google Scholar]
  36. Vadas P., Pruzanski W., Stefanski E., Sternby B., Mustard R., Bohnen J., Fraser I., Farewell V., Bombardier C. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med. 1988 Jan;16(1):1–7. doi: 10.1097/00003246-198801000-00001. [DOI] [PubMed] [Google Scholar]
  37. Veterans Administration Systemic Sepsis Cooperative Study Group Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987 Sep 10;317(11):659–665. doi: 10.1056/NEJM198709103171102. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES